These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38578904)

  • 1. Emerging Role of Environmental Epitranscriptomics and RNA Modifications in Parkinson's Disease.
    Gionco JT; Bernstein AI
    J Parkinsons Dis; 2024; 14(4):643-656. PubMed ID: 38578904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping the epigenetic modifications of DNA and RNA.
    Zhao LY; Song J; Liu Y; Song CX; Yi C
    Protein Cell; 2020 Nov; 11(11):792-808. PubMed ID: 32440736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring epitranscriptomics for crop improvement and environmental stress tolerance.
    Yang X; Patil S; Joshi S; Jamla M; Kumar V
    Plant Physiol Biochem; 2022 Jul; 183():56-71. PubMed ID: 35567875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic mechanisms in Parkinson's disease.
    Feng Y; Jankovic J; Wu YC
    J Neurol Sci; 2015 Feb; 349(1-2):3-9. PubMed ID: 25553963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenomics in stress tolerance of plants under the climate change.
    Kumar M; Rani K
    Mol Biol Rep; 2023 Jul; 50(7):6201-6216. PubMed ID: 37294468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the Expression and Epigenetics of Genes Involved in Monogenic Forms of Parkinson's Disease Influence Sporadic Forms?
    Lanore A; Lesage S; Mariani LL; Menon PJ; Ravassard P; Cheval H; Corti O; Brice A; Corvol JC
    Genes (Basel); 2022 Mar; 13(3):. PubMed ID: 35328033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epitranscriptome sequencing technologies: decoding RNA modifications.
    Li X; Xiong X; Yi C
    Nat Methods; 2016 Dec; 14(1):23-31. PubMed ID: 28032622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic analysis of N6-methyladenosine modification genes in Parkinson's disease.
    Qin L; Min S; Shu L; Pan H; Zhong J; Guo J; Sun Q; Yan X; Chen C; Tang B; Xu Q
    Neurobiol Aging; 2020 Sep; 93():143.e9-143.e13. PubMed ID: 32371107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetics in Parkinson's Disease.
    Pavlou MAS; Outeiro TF
    Adv Exp Med Biol; 2017; 978():363-390. PubMed ID: 28523556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications.
    Porcellini E; Laprovitera N; Riefolo M; Ravaioli M; Garajova I; Ferracin M
    Cancer Lett; 2018 Apr; 419():84-95. PubMed ID: 29360561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA Modifications and Epigenetics in Modulation of Lung Cancer and Pulmonary Diseases.
    Teng PC; Liang Y; Yarmishyn AA; Hsiao YJ; Lin TY; Lin TW; Teng YC; Yang YP; Wang ML; Chien CS; Luo YH; Chen YM; Hsu PK; Chiou SH; Chien Y
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Perspectives in Epitranscriptomics.
    Santos-Pujol E; Quero-Dotor C; Esteller M
    Curr Opin Genet Dev; 2024 Aug; 87():102209. PubMed ID: 38824905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Roles of N6-Methyladenosine (m6A) Epitranscriptomics in Toxicology.
    Malovic E; Ealy A; Kanthasamy A; Kanthasamy AG
    Toxicol Sci; 2021 Apr; 181(1):13-22. PubMed ID: 33616673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation in Parkinson's disease.
    Wüllner U; Kaut O; deBoni L; Piston D; Schmitt I
    J Neurochem; 2016 Oct; 139 Suppl 1():108-120. PubMed ID: 27120258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Census and Categorization Method of Epitranscriptomic Marks.
    Mathlin J; Le Pera L; Colombo T
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic and Epitranscriptomic Control in Prostate Cancer.
    López J; Añazco-Guenkova AM; Monteagudo-García Ó; Blanco S
    Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalities.
    Ammal Kaidery N; Tarannum S; Thomas B
    Neurotherapeutics; 2013 Oct; 10(4):698-708. PubMed ID: 24030213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epitranscriptomics of Ischemic Heart Disease-The IHD-EPITRAN Study Design and Objectives.
    Sikorski V; Karjalainen P; Blokhina D; Oksaharju K; Khan J; Katayama S; Rajala H; Suihko S; Tuohinen S; Teittinen K; Nummi A; Nykänen A; Eskin A; Stark C; Biancari F; Kiss J; Simpanen J; Ropponen J; Lemström K; Savinainen K; Lalowski M; Kaarne M; Jormalainen M; Elomaa O; Koivisto P; Raivio P; Bäckström P; Dahlbacka S; Syrjälä S; Vainikka T; Vähäsilta T; Tuncbag N; Karelson M; Mervaala E; Juvonen T; Laine M; Laurikka J; Vento A; Kankuri E
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34205699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitranscriptomic signatures in stem cell differentiation to the neuronal lineage.
    Șelaru A; Costache M; Dinescu S
    RNA Biol; 2021 Oct; 18(sup1):51-60. PubMed ID: 34582322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Regulation of RNA Modification Systems: The Next Frontier in Epitranscriptomics?
    Schaefer MR
    Genes (Basel); 2021 Feb; 12(3):. PubMed ID: 33652758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.